Evidence map›Paper›PMID 26622510›Full record

ArticleExperimental and therapeutic medicine2015

Nilotinib rapidly reverses breakpoint cluster region-Abelson oncogene fusion gene and M244V mutations in a patient with chronic myelogenous leukemia: A case report.

Xuliang Shen, Meixiang Zhang, Yifan Shen, Wenzhi Shi, Wei Liu, W U Wei

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Imatinib‑induced gynecomastia: A case report.Experimental and therapeutic medicine · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xuliang ShenDepartment of Hematology, Heping Hospital of Changzhi Medical College, Changzhi, Shanxi 046000, P.R. China.
Meixiang ZhangDepartment of Hematology, Beijing Rehabilitation Hospital of Capital Medical University, Beijing 100144, P.R. China.
Yifan ShenDepartment of Hematology, Heji Hospital of Changzhi Medical College, Changzhi, Shanxi 046000, P.R. China.
Wenzhi ShiDepartment of Hematology, Heping Hospital of Changzhi Medical College, Changzhi, Shanxi 046000, P.R. China.
Wei LiuDepartment of Hematology, Heping Hospital of Changzhi Medical College, Changzhi, Shanxi 046000, P.R. China.
W U WeiDepartment of Hematology, Heping Hospital of Changzhi Medical College, Changzhi, Shanxi 046000, P.R. China.
Changzhi Medical College · CNChina Rehabilitation Research Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myelogenous leukemia (CML) is a condition characterized by a balanced genetic translocation, t (9;22) (q34;q11.2), which leads to a fusion of the Abelson oncogene (

Indexed as

breakpoint cluster region-Abelson oncogenechronic myeloid leukemiaM244V mutationnilotinibtyrosine kinase inhibitors

Identifiers

PMID26622510
PMCPMC4578011
OpenAlexW1494081104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.